
[ Fri, Jan 13th 2023 ]: WOPRAI
[ Fri, Jan 13th 2023 ]: WOPRAI
[ Fri, Jan 13th 2023 ]: WOPRAI
[ Fri, Jan 13th 2023 ]: WOPRAI
[ Fri, Jan 13th 2023 ]: WOPRAI
[ Fri, Jan 13th 2023 ]: WOPRAI
[ Fri, Jan 13th 2023 ]: WOPRAI
[ Fri, Jan 13th 2023 ]: WOPRAI
[ Fri, Jan 13th 2023 ]: WOPRAI
[ Fri, Jan 13th 2023 ]: WOPRAI
[ Fri, Jan 13th 2023 ]: WOPRAI
[ Fri, Jan 13th 2023 ]: WOPRAI
[ Fri, Jan 13th 2023 ]: WOPRAI
[ Fri, Jan 13th 2023 ]: WOPRAI
[ Fri, Jan 13th 2023 ]: WOPRAI
[ Fri, Jan 13th 2023 ]: WOPRAI
[ Fri, Jan 13th 2023 ]: WOPRAI
[ Fri, Jan 13th 2023 ]: WOPRAI
[ Fri, Jan 13th 2023 ]: WOPRAI
[ Fri, Jan 13th 2023 ]: WOPRAI
[ Fri, Jan 13th 2023 ]: WOPRAI
[ Fri, Jan 13th 2023 ]: WOPRAI
[ Fri, Jan 13th 2023 ]: WOPRAI
[ Fri, Jan 13th 2023 ]: WOPRAI
[ Fri, Jan 13th 2023 ]: WOPRAI
[ Fri, Jan 13th 2023 ]: WOPRAI
[ Fri, Jan 13th 2023 ]: WOPRAI
[ Fri, Jan 13th 2023 ]: WOPRAI
[ Fri, Jan 13th 2023 ]: WOPRAI
[ Fri, Jan 13th 2023 ]: WOPRAI
[ Fri, Jan 13th 2023 ]: WOPRAI
[ Fri, Jan 13th 2023 ]: WOPRAI
[ Fri, Jan 13th 2023 ]: WOPRAI
[ Fri, Jan 13th 2023 ]: WOPRAI
[ Fri, Jan 13th 2023 ]: WOPRAI
[ Fri, Jan 13th 2023 ]: WOPRAI
[ Fri, Jan 13th 2023 ]: WOPRAI
[ Fri, Jan 13th 2023 ]: WOPRAI
[ Fri, Jan 13th 2023 ]: WOPRAI
[ Fri, Jan 13th 2023 ]: WOPRAI
[ Fri, Jan 13th 2023 ]: WOPRAI
[ Fri, Jan 13th 2023 ]: WOPRAI
[ Fri, Jan 13th 2023 ]: WOPRAI
[ Fri, Jan 13th 2023 ]: WOPRAI
[ Fri, Jan 13th 2023 ]: WOPRAI
[ Fri, Jan 13th 2023 ]: WOPRAI
[ Fri, Jan 13th 2023 ]: WOPRAI
[ Fri, Jan 13th 2023 ]: WOPRAI
Asthika Goonewardene Maintained (STRO) at Strong Buy with Increased Target to $25 on, Jan 13th, 2023


🞛 This publication is a summary or evaluation of another publication
Asthika Goonewardene of Truist Securities, Maintained "Sutro Biopharma, Inc." (STRO) at Strong Buy with Increased Target from $21 to $25 on, Jan 13th, 2023.
Asthika has made no other calls on STRO in the last 4 months.
There are 2 other peers that have a rating on STRO. Out of the 2 peers that are also analyzing STRO, 0 agree with Asthika's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Asthika
- Edward Tenthoff of "Piper Sandler" Maintained at Buy with Increased Target to $18 on, Tuesday, January 10th, 2023
- Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $20 on, Wednesday, November 9th, 2022